
    
      Phase 1a part:

      To evaluate safety and tolerability in combination of OBP-301 and Pembrolizumab in patient
      with advanced or metastatic solid tumor and to determine recommended dose in phase 1b part.

      Phase 1b part:

      To evaluate safety and potential efficacy in combination of OBP-301 and Pembrolizumab in
      patients in expanded arm.
    
  